Advertisement
Australia markets open in 6 hours 35 minutes
  • ALL ORDS

    8,010.50
    -5.30 (-0.07%)
     
  • AUD/USD

    0.6671
    +0.0013 (+0.19%)
     
  • ASX 200

    7,769.70
    -8.40 (-0.11%)
     
  • OIL

    81.52
    -0.05 (-0.06%)
     
  • GOLD

    2,344.50
    -2.40 (-0.10%)
     
  • Bitcoin AUD

    97,784.16
    +720.30 (+0.74%)
     
  • CMC Crypto 200

    1,384.92
    +47.17 (+3.53%)
     

Bioventus to Report First Quarter of Fiscal Year 2024 Financial Results on May 7, 2024

Bioventus, Inc.
Bioventus, Inc.

DURHAM, N.C., April 29, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2024 before the market opens on Tuesday, May 7, 2024. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update.

To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call.

A live webcast of the call and accompanying materials will also be provided on the “Investor Relations” section of the Company's website at https://ir.bioventus.com/. The webcast will be archived at the same site and available for replay until May 6, 2025.

ADVERTISEMENT

About Bioventus
Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for Pain Treatments, Restorative Therapies and Surgical Solutions. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.bioventus.com and follow the Company on LinkedIn and Twitter. Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.

Investor and Media Inquiries:
Dave Crawford
919-474-6787
Dave.Crawford@bioventus.com